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ABSTRACT 
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening 
thrombotic microangiopathy characterized by microangiopathic hemolytic 
anemia, severe thrombocytopenia, and organ ischemia linked to disseminated 
microvascular platelet rich-thrombi. TTP is specifically related to a severe 
deficiency in ADAMTS13 (a disintegrin and metalloprotease with 
thrombospondin type 1 repeats, member 13), the specific von Willebrand 
factor-cleaving protease. ADAMTS13 deficiency is most frequently acquired 
via ADAMTS13 autoantibodies, but rarely, it is inherited via mutations of 
the ADAMTS13 gane. The first acute episode of TTP usually occurs during 
adulthood, with a predominant anti – ADAMTS13 autoimmune etiology. In 
rare cases, however, TTP begins as soon as childhood, with frequent 
inherited forms. TTP is 2 – fold more frequent in women, and its outcome is 
characterized by a relapsing tendency. 
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Introduction. TTP is thought to be a rare disease. Over one series, the frequency was 
approximately 1 in 50000 hospital admissions. Over a 25 year period in the Sacramento, California 
region (population at risk, 1.2 million) at least 176 documented cases of TTP were reported. Analysis 
of a French national registry found that the rate of TTP in France was 13 cases per million population.  
Untreated TTP has a mortality rate of as high as 90%. With plasma exchange the mortality rate 
is reduced to 10-20%. Patients with TTP have unusually large multimers of von willebrand factor (WF) 
in their plasma and the lack a plasma protease that is responsible for the breakdown of these ultralarge 
WF multimers. In the congenital form of TTP, mutations in the gene encoding this protease have been 
described. This protease has been isolated and cloned and is designated ADAMTS13. To make an 
accurate diagnosis, the clinician must recognice the similarity between thrombotic thrombocytopenic 
purpura (TTP) and hemolytic – uremic syndrome (Hus). The differential diagnosis also includes immune 
thrombocytopenic purpura (ITP) and disseminated intrawascular coagulation (Dic). 
In addition to the microangiopathic hemolytic anemia and consumption thrombocytopenia, 
classical parameters for hemolysis show a high reticulocyte count (>120X109/L), an undetectable 
serum haptoglobin concentration, and an elevated lactate dehydrogenase level, a marker for tissue 
damage. The fresence of schistocytes on the blood smear (helmet cells; small, irregular triangular, or 
crescent –shaped cells; pointed projections; and lack of central pallor) with a confident threshold value 
of 1% is the morphologic hallmark of the disease. Except in some associated autoimmune contexts 
(SLE), the erythrocyte Coombs' test is negative, Standard coagulation parameters are usually normal. 
MEDICINE 
Science Review                                                                                                                  ISSN 2544-9346 
 
                                                                                     3(20), March 2019  13 
 
Renal testing may show proteinuria, hematuria, and sometimes increased plasma urea and creatinine 
levels. An increased cardiac troponin level (>0.1 μis) is present in up to 60% of cases, the majority of 
whom have no clinical cardiac involvement. Electrocardiogram changes, mainly repolarization 
disorders, are present in 10% of cases. Point-based TTP prediction scores have been validated to 
predict an acquired ADAMTS13 deficiency. These scores include platelet count, serum creatinine 
level, and either detectable antinuclear antibodies or d-dimer, reticulocytes, and indirect bilirubin.  
As these standard investigations are not specific for TTP and may be present in the 
miscellaneous differential diagnosis for TTP, they should be complemented by analysis of 
ADAMTS13, the unique marker sensitive and specific for TTP. 
Clinical spectrum of TTP 
Today, the historical clinical pentad of fever, thrombocytopenia, microangiopathic hemolytic 
anemia, neurological symptoms, and renal insufficiency that used to define TTP appears obsolete, as 
several cohort studies have clearly demonstrated that these 5 symptoms were present in less than 10% of 
patients with an acute TTP. The almost constant signs of TTP remain severe thrombocytopenia (typically 
<30 x 109/L) and microangiopathic hemolytic anemia characterized by schistocytes on the blood smear, 
often associated with corresponding symptoms (ie, skin and mucosal hemorrhage, weakness, and dispnoe). 
Symptoms related to o ischemia/infarction mostly concern the brain (-60% of patients have neurologic 
symptoms at presentation, with a broad range from headache and confusion to stroke, coma, and seizures). 
Heart ischemia is also frequent (-25% of patients, ranging from isolated electrocardiographic abnormalities 
to myocardial infarction). as well as mesenteric ischemia (-35%) causing abdominal pain and seizures. 
Heart ischemia is also freqienr (-25%) of an isolated proteinuria/hematuria; acute renal failure is unusual in 
TTP, with typically a serum creatinine level below 2 mg/dL at presentation.  
Rapid recognition of TTP is crucial to initiate appropriate treatment. The first-line therapy for 
acute TTP is sased on daily therapeutic plasma exchange supplying deficient ADAMTS13, with or 
without steroids. Additional immune modulators targeting ADAMTS13 autoantibodies are mainly 
based on steroids and humanized anti–CD20 monoclinal antibody rituximab. In refractory or 
unresponsive TTP, more intensive tharapies including twice-daily plasma exchange; pulses of 
cyclophosphamide, vincristine, or cyclosporine A; salvage splenectomy are considered. New drugs 
including N-acetylcysteine, bortezomib, recombinant ADAMTS13, and caplacizumab show promise 
in the management of TTP. Also, long-term follow-up of patients with TTP is crucial to identisy the 
occurrence of other autoimmune diseases, to control relapses, and to evaluate psychophysical 
sequelae. The overall response rate to plasma exchange is 75-90%. The early mortality rate is 10-20%. 
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